Neurological therapeutics specialist Neurocrine Biosciences (NASDAQ:NBIX) reported mixed fourth-quarter earnings on Thursday, Feb. 6. Despite a slight miss on revenue expectations, its adjusted earnings per share (EPS) beat estimates significantly.

Overall, the quarter showcased strong performance, particularly from the flagship prescription medication Ingrezza, underscoring the effectiveness of its strategic initiatives.

Source: Neurocrine Biosciences. Note: Analyst consensus estimates for the quarter provided by FactSet. YOY = Year over year. SG = Selling, general, and administrative expenses

Continue reading

Source Fool.com